Merck takes on Lilly/Nektar in IL-2 with $1.85bn Pandion buyMerck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for Share XMerck takes on Lilly/Nektar in IL-2 with $1.85bn Pandion buyhttps://pharmaphorum.com/news/merck-takes-on-lilly-nektar-in-il-2-with-1-85bn-pandion-buy/
Astellas cuts $795m deal with Pandion for type 1 diabetes drugsAstellas Pharma is boosting its early-stage pipeline with a $45 million upfront deal to license bispecific antibodies from Share XAstellas cuts $795m deal with Pandion for type 1 diabetes drugshttps://pharmaphorum.com/news/astellas-biotech-deal-pandion-diabetes/
